PVALB, a new hürthle adenoma diagnostic marker identified through gene expression

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 1, 2011, Pages

  Cerutti, Janete M ^a   Oler, Gisele ^a   Delcelo, Rosana ^a   Gerardt, Rene ^b   Michaluart Jr , Pedro ^b   De Souza, Sandro J ^c   Galante, Pedro A F ^c   Huang, Peng ^d   Riggins, Gregory J ^d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVALBUMIN;

ADENOMA; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; GENETIC MARKER; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; HURTHLE CELL ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

EID: 78650855487     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1318     Document Type: Article

References (26)

1. Mazzaferri EL 1993 Management of a solitary thyroid nodule. N Engl J Med 328:553-559
2. Ezzat S, Sarti DA, Cain DR, Braunstein GD 1994 Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 154:1838-1840
3. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ 2008 Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 36:425-437
4. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J, Riggins GJ 2004Apreoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113:1234-1242
5. Cerutti JM, Latini FR, Nakabashi C, Delcelo R, Andrade VP, Amadei MJ, Maciel RM, Hojaij FC, Hollis D, Shoemaker J, Riggins GJ 2006 Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res 12:3311-3318
6. Matsumoto F, Fujii H, Abe M, Kajino K, Kobayashi T, Matsumoto T, Ikeda K, Hino O 2006 A novel tumor marker, Niban, is expressed in subsets of thyroid tumors and Hashimoto's thyroiditis. Hum Pathol 37:1592-1600
7. Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, Kinzler KW, Velculescu VE 2002 Using the transcriptome to annotate the genome. Nat Biotechnol 20:508-512
8. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ 1999 A public database for gene expression in human cancers. Cancer Res 59: 5403-5407 (Pubitemid 29526444)
9. Galante PA, Trimarchi J, Cepko CL, de Souza SJ, Ohno-Machado L, Kuo WP 2007 Automatic correspondence of tags and genes (ACTG): a tool for the analysis of SAGE, MPSS and SBS data. Bioinformatics 23:903-905
10. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW 1997 Gene expression profiles in normal and cancer cells. Science 276:1268-1272
11. Suzuki R, Shimodaira H 2006 Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22: 1540-1542
12. Cerutti JM, Oler G, Michaluart Jr P, Delcelo R, Beaty RM, Shoemaker J, Riggins GJ 2007 Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res 67:7885-7892
13. Oler G, Camacho CP, Hojaij FC, Michaluart Jr P, Riggins GJ, Cerutti JM 2008 Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 14:4735-4742
14. Máximo V, Sobrinho-Simões M 2000 Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 437:107-115
15. Belchetz G, Cheung CC, Freeman J, Rosen IB, Witterick IJ, Asa SL 2002 Hurthle cell tumors: using molecular techniques to define a novel classification system. Arch Otolaryngol Head Neck Surg 128:237-240
16. Montone KT, Baloch ZW, LiVolsi VA 2008 The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med 132:1241-1250
17. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA 2006 Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 17:225-234
18. Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, Zhao Y, Goellner JR, Sebo TJ, Grebe SK, Eberhardt NL, McIver B 2005 PPARγ staining as a surrogate for PAX8/PPARγ fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab 90:463-468
19. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR, Williams D, Sobrinho-Simões M 2005 Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 92:1892-1898
20. Masood S, Auguste LJ, Westerband A, Belluco C, Valderama E, Attie J 1993 Differential oncogenic expression in thyroid follicular and Hurthle cell carcinomas. Am J Surg 166:366-368
21. Farrand K, Delahunt B, Wang XL, McIver B, Hay ID, Goellner JR, Eberhardt NL, Grebe SK 2002 High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene. J Clin Endocrinol Metab 87:4715-4721
22. Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL 2000 Molecular basis off hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85:878-882
23. Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, Lazzi S, Monaco M, Mazzuchelli L, Tosi P, Santoro M, Fusco A 2002 The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 87:364-369
24. Mills SC, Haq M, Smellie WJ, Harmer C 2009 Hurthle cell carcinoma of the thyroid: Retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol 35:230-234
25. Erickson LA, Jalal SM, Goellner JR, Law ME, Harwood A, Jin L, Roche PC, Lloyd RV 2001 Analysis of Hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization. Am J Surg Pathol 25:911-917
26. Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M 2005 Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res 11:6558-6566